US 12,390,621 B1
System and method for selective pressure-controlled therapeutic delivery
Aravind Arepally, Atlanta, GA (US); James E. Chomas, Denver, CO (US); Bryan Pinchuk, Miami, FL (US); and David Benjamin Jaroch, Arvada, CO (US)
Assigned to TriSalus Life Sciences, Inc., Westminster, CO (US)
Filed by TriSalus Life Sciences, Inc., Westminster, CO (US)
Filed on Feb. 14, 2022, as Appl. No. 17/671,296.
Application 17/671,296 is a continuation of application No. 15/871,326, filed on Jan. 15, 2018, granted, now 11,400,263.
Application 15/871,326 is a continuation in part of application No. 15/703,951, filed on Sep. 13, 2017, granted, now 10,780,250, issued on Sep. 22, 2020.
Claims priority of provisional application 62/396,622, filed on Sep. 19, 2016.
This patent is subject to a terminal disclaimer.
Int. Cl. A61M 25/10 (2013.01); A61F 2/01 (2006.01); A61L 29/16 (2006.01); A61M 39/22 (2006.01); B05D 1/18 (2006.01); B05D 3/02 (2006.01); A61M 25/01 (2006.01)
CPC A61M 25/10 (2013.01) [A61F 2/013 (2013.01); A61L 29/16 (2013.01); B05D 1/18 (2013.01); B05D 3/0272 (2013.01); A61F 2240/001 (2013.01); A61L 2430/36 (2013.01); A61M 25/0108 (2013.01); A61M 2025/1052 (2013.01); A61M 39/22 (2013.01); A61M 2039/229 (2013.01); A61M 2205/3334 (2013.01); A61M 2230/06 (2013.01); A61M 2230/30 (2013.01)] 25 Claims
OG exemplary drawing
 
1. A method for delivering a therapeutic agent for treatment of a solid tumor in a target organ, the target organ in fluid communication with a vein in a patient, the method comprising:
a) introducing a treatment system into the vein of the patient, the treatment system comprising a microvalve comprising a filamentary braid coated with a polymeric filter comprising pores, the microvalve movable between a collapsed configuration for delivery through the vein, and an expanded configuration adapted to extend across the vein;
b) advancing the microvalve into the vein in the collapsed configuration, the vein subject to a systemic venous pressure on a distal side of the microvalve; then
c) expanding the microvalve into the expanded configuration to block flow within the vein in a distal to proximal direction past the microvalve; and
d) injecting the therapeutic agent at a first pressure, distal of the microvalve and into the vein to cause the therapeutic agent to flow through the vein and into the target organ at a pressure higher than the systemic venous pressure, wherein a pressure of the injected therapeutic agent generates a net increase in fluid pressure in the vein of 10 mmHg to 200 mmHg above the systemic venous pressure.